Protection Against Influenza B Viruses by Human Monoclonal Antibodies that Target the Neuraminidase Active Site
Anders Madsen(University of Bergen), Ali H. Ellebedy(Washington University in St. Louis), Shirin Strohmeier(Icahn School of Medicine at Mount Sinai), Tingting Lei(Washington University in St. Louis), Aaron J. Schmitz(Washington University in St. Louis), Philip A. Mudd(Washington University in St. Louis), Meagan McMahon(Seqirus (United States)), Daved H. Fremont(Washington University in St. Louis), Jackson S. Turner(Washington University in St. Louis), Florian Krammer(Semmelweis University), Rebecaa Cox(National Influenza Center), Ya-Nan Dai(Washington University in St. Louis), Mostafa Amor(Washington University in St. Louis), Viviana Simon(Icahn School of Medicine at Mount Sinai), Wafaa B. Alsoussi(Washington University in St. Louis), Bassem Mohamed(Washington University in St. Louis), Jessica Tan(Icahn School of Medicine at Mount Sinai)
Cited by 0
Related Papers
Immunology of COVID-19: Current State of the Science
|Immunity|2020|1.8k
Influenza
|Nature Reviews Disease Primers|2018|1.5k
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
|Nature Medicine|2021|1k
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
|Cell Host & Microbe|2021|851